Care Innovations: Integration of Flash Glucose Monitoring in the Transition of Care from Inpatient to Outpatient

Abstract

In 2020, the United States had an increase in hospitalizations due to SARS-CoV-2 (COVID-19). Many of these patients also had co-morbid diabetes. In order to minimize patient –provider contact the Food and Drug Administration (FDA) granted emergency approval for inpatient use of continuous glucose monitors (CGM). Implementing the use of new technology during a pandemic does not come without challenges, as a result it was deferred to time of discharge. In this piece we address the patient, nursing and provider benefits and pitfalls of integrating CGM in patient care for persons with diabetes who have never used CGM technology in the past.